期刊文献+

ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES AGAINST ANTI-OVARIAN CARCINOMA MONOCLONAL ANTIBODY COC166-9 GENERATION AND APPLICATION 被引量:5

ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES AGAINST ANTI-OVARIAN CARCINOMA MONOCLONAL ANTIBODY COC166-9 GENERATION AND APPLICATION
原文传递
导出
摘要 Anri-idiotypic monoclonal antibody (Mab Ab2 ) by MAb COC166-9 against ovarian serous papillary adenocarcinoma was prepared. Hybridomas of Ab2 screened by sandwich ELISA and immunocompetitive inhibition tests were procured and named as 6B11 and 1H12. The number of their chromosomes were 93 and 91, and DNA analysis also proved the characteristics of hybridomas. These Ab2s could induce delayed type hypersensitivity (DTH), the cellular immune response. The results of the immune reaction of 6B11 with SKOV3 (ovarian carcinoma cell line) were similar to OC166-9 (Ag), the positive control, while 1H12 was weaker. Anti-and-idiotypic antibody (Ab3) was also raised by 6B11 and 1H12 respectively. They all showed positive immunohistochemical stainings with ovarian serous adenocarcinoma tissue sections and immunocytochemical stainings with SKOV3 cells as was shown by COC166-9. In the antibody dependent cell mediated cytotoxicity (ADCC) tests, they showed no differences against SKOV3 as compared with COC166-9. We anticipate that 6B11 and 1H12 may be used as vaccines against ovarian carcinoma and may provide a clue for its prevention and treatment. Anri-idiotypic monoclonal antibody (Mab Ab2 ) by MAb COC166-9 against ovarian serous papillary adenocarcinoma was prepared. Hybridomas of Ab2 screened by sandwich ELISA and immunocompetitive inhibition tests were procured and named as 6B11 and 1H12. The number of their chromosomes were 93 and 91, and DNA analysis also proved the characteristics of hybridomas. These Ab2s could induce delayed type hypersensitivity (DTH), the cellular immune response. The results of the immune reaction of 6B11 with SKOV3 (ovarian carcinoma cell line) were similar to OC166-9 (Ag), the positive control, while 1H12 was weaker. Anti-and-idiotypic antibody (Ab3) was also raised by 6B11 and 1H12 respectively. They all showed positive immunohistochemical stainings with ovarian serous adenocarcinoma tissue sections and immunocytochemical stainings with SKOV3 cells as was shown by COC166-9. In the antibody dependent cell mediated cytotoxicity (ADCC) tests, they showed no differences against SKOV3 as compared with COC166-9. We anticipate that 6B11 and 1H12 may be used as vaccines against ovarian carcinoma and may provide a clue for its prevention and treatment.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 1994年第2期21-25,共5页 中华医学杂志(英文版)
  • 相关文献

同被引文献22

  • 1崔恒,昌晓红,冯捷,刘蓓,曹善津,李小平,钱和年.模拟卵巢癌抗原的人源化抗独特型抗体的构建与表达[J].中国妇产科临床杂志,2002,3(1):44-47. 被引量:4
  • 2张香云,钱和年,邱并生,崔恒,冯捷,黄华梁,傅天云,李文锦,王建六,周萍,李小平.6B11卵巢癌抗独特型单链抗体表达及序列分析[J].北京医科大学学报,1996,28(4):252-255. 被引量:18
  • 3.COC166-9 (Ab1) and 6B11 (Ab2) beta[].Hybridoma and Hybridomics.2003
  • 4SUN QM,JIANG HC,XU WM,LIU X,DAI CB,SUN MS.HIGH-LEVEL EXPRESSION AND PURIFICATION OF RECOMBINANT HUGM-CSF (9-127)/IL-6 (29-184) FUSION PROTEIN IN ESCHERICHIA COLI[].Protein Expression and Purification.2005
  • 5CHANG X,CUI H,FENG J,LI Y,LIU B,CAO S,ET AL.PREPARATION OF HUMANIZED OVARIAN CARCINOMA ANTI-IDIOTYPIC MINIBODY[].Hybridoma and Hybridomics.2003
  • 6Qian HN,Feng J,Cui H,et al.Generation and characterization of monoclonal antibody COC166-9 to human epithelial ovarian adenocarcinoma[].Soshiran (The Sino-Japanese Journal of Allergology and Immunology).1988
  • 7Xu X,Clarke P,Szalai G,et al.Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein[].Cancer Research.2000
  • 8Cui H,Chang X H,Liu B,et al.The anti-tumor immune responses induced by a fusion protein of ovarian carcinoma anti-idiotypic antibody 6B11ScFv and Murine GM-CSF in BALB/c mice[].International Journal of Gynecological Cancer.2004
  • 9Foon K A,Lutzky J,Baral R N,et al.Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2[].Journal of Clinical Oncology.2000
  • 10Reinartz S,Kohler S,Schlebusch H,et al.Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)[].Clinical Cancer Research.2004

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部